Remarks

This application is amended in the Specification to reflect the priority claimed to the relevant U.S. and UK applications. Claims 1-37 have been canceled. Claims 38-44 are newly added. Applicants respectfully submit that no new matter is introduced by these amendments.

tehisin Oct. 03, 2003

Respectfully submitted,

Keitii D. Flutchiilson

Registration No. 43,687 Agouron Pharmaceuticals, Inc./A Pfizer Company 10777 Science Center Drive San Diego, Ca 92121 (858) 622-8807